A clinical practice guideline on Multiple Sclerosis is being developed for use in the NHS in England and Wales. We have answered some frequently asked questions on our clinical guidelines at the end of this information; for more information on NICE's guideline development process, click here.
The consultation documents
There are three documents presented here - the full version of the guideline, the short version and information explaining the recommendations in easy-to-understand language - have been prepared for the second round of consultation with the stakeholders registered for this guideline topic.
It is essential that you use the proforma when sending us comments, specifying which section you are referring to. The form is attached for you to email back to email@example.com.
Note that the provisional guideline recommendations presented here do not constitute the Institute's formal guidance on this guideline topic. The recommendations are provisional and may change after consultation.
The full version describes the evidence and views that have been considered, and sets out the provisional guideline recommendations that have been developed - these may have been revised in the light of comments made during the first consultation period.
Full guideline - section 9 (second consultation)
Multiple Sclerosis: Full guideline - section 10 (second consultation)
The short version presents the provisional guideline recommendations only; again the recommendations may have been revised following the first round of consultation. (It is the finalised short version that is issued to the NHS as guidance.)
The lay version has been prepared to help people who may be affected by the guideline recommendations understand what the provisional recommendations mean; this information was not available during the first consultation period.
Points to consider in the second consultation
During this consultation period, you may want to:
The Institute is now inviting comments from the registered stakeholders for this guideline. Although individuals may comment on these documents, we advise you to contact the registered stakeholder organisation that most closely represents your interests and pass your comments to that organisation. The registered stakeholders for this guideline are listed on this website.
Comments made on these documents by registered stakeholders will be posted on the NICE website when the guidelines are published, together with the name of the organisation that submitted the comments. Informative comments from individuals or non-registered stakeholders will be summarised and the summary will also be posted on the website.
Please do not include personal medical information about yourself or another person from which your or the person's identity could be ascertained.
Send your comments using the proforma via email to: firstname.lastname@example.org . Alternatively you can send the proforma, marked 'Guidelines - Multiple Sclerosis' to: Bobbie Lloyd, National Institute for Clinical Excellence, 11 Strand, London WC2N 5HR or fax them to the Institute on: 020 7968 2763. Please be clear whether your comments refer to the full guideline, the short version or the lay version.
The key dates for this guideline are:
Closing date for comments: 7 April 2003
Publication of guideline: June 2003
Frequently asked questions about NICE clinical guidelines
Why was this guideline developed?
The Department of Health and the Welsh Assembly Government selects the guidelines topics for NICE.
Who develops the recommendations in the guideline?
The guideline is developed by one of the National Collaborating Centres that NICE has established. Once a guideline is commissioned from a National Collaborating Centre, the Centre sets up a Guideline Development Group to review the evidence on the clinical and cost effectiveness of the guideline options and formulate the guideline recommendations. The Guideline Development Group includes healthcare professionals involved in the clinical area and lay representatives with knowledge and experience of the patient and carer issues surrounding the medical condition(s).
Who can become a stakeholder?
Information on the groups and companies that can register as stakeholders for a particular guideline is included in The Guideline Development Process - Information for Stakeholders. For a list of the stakeholders that have registered for this guideline, click here.
What happens next?
The provisional guideline recommendations will be reconsidered in the light of the comments received. The final guideline will be prepared and submitted to the Institute, which may issue the short version and the accompanying information explaining the recommendations in easy-to-understand language as formal guidance to the NHS in England and Wales.
Where can I find out more?
NICE has produced three documents that outline the guideline development process. All three can be downloaded from this site.
Copyright ©2003 National Institute for Clinical Excellence